Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

The FDA has removed the REMS program requirements for embryofetal toxicity risk from all endothelin receptor antagonist medications.

The FDA published over 200 response letters sent as replies to drug and biological product applications in order to increase transparency.

Patients with severe asthma who initiate biologics may reduce their risk for oral corticosteroids (OCS)-related new-onset adverse outcomes.

Increased risk for all-cause and CVD mortality in OSA may be linked to a severe phenotype marked by objective excessive daytime sleepiness.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Hospital staffing shortages are expected as applicants from foreign countries are unable to get visas under the Trump administration.

Infliximab and efzofitimod may be effective in pulmonary sarcoidosis and tofacitinib and adalimumab in cutaneous sarcoidosis.

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

Individuals with vs without knee, hip, or hand OA were associated with a significantly increased risk for sleep apnea.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.